Fabrice André
0000-0001-5795-8357
Publication & Citation Trends
Publications
0 total
Return to work among self-employed breast cancer survivors from the CANTO cohort.
Cited by 0
Semantic Scholar
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.
Cited by 0
Semantic Scholar
Relevance of timing intake of everolimus (EVE) combined with adjuvant endocrine therapy (ET) in patients (pts) with high-risk early breast cancer: Results of a sub-study of the UCBG-UNIRAD trial.
Cited by 1
Semantic Scholar
Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer.
Cited by 54
Semantic Scholar
DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC.
Cited by 25
Semantic Scholar
p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane
Cited by 2
Semantic Scholar
Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the Recurrence Score in node-positive breast cancer: Independent validation in the PACS-01 trial.
Cited by 0
Semantic Scholar
Antibody-drug conjugates in lung and breast cancer: Current evidence and future directions - a position statement from the ETOP IBCSG Partners Foundation.
Cited by 27
Semantic Scholar
Research Topics
Cancer Genomics and Diagnostics
(491)
Advanced Breast Cancer Therapies
(384)
HER2/EGFR in Cancer Research
(274)
Breast Cancer Treatment Studies
(250)
Lung Cancer Treatments and Mutations
(198)
Affiliations
Université Paris-Sud
Champalimaud Foundation
Agency for Science, Technology and Research
Roche (Switzerland)
Hebron University